WILMINGTON, N.C.– Catalyst Clinical Research has been named the winner of the Excellence in Clinical Trial Management category at the prestigious Fierce CRO Awards, a recognition that spotlights top-performing contract research organizations in the global life sciences sector.
Presented by Fierce Biotech, the annual awards celebrate innovation, performance, and leadership among CROs that play a vital role in advancing clinical research and drug development. Catalyst was singled out for its adaptable, high-quality trial management and its ability to exceed client expectations across complex clinical studies.
In one standout trial cited by the awards committee, Catalyst’s recommendations on modifying the study design contributed to a highly successful outcome. The trial not only surpassed enrollment targets but also produced compelling endpoint results, paving the way for the sponsor to seek Breakthrough Therapy Designation and move toward a potential registrational submission.
“Winning this award is a tremendous honor,” said Nik Morton, President and CEO of Catalyst Clinical Research. “It reflects the passion, expertise, and hard work of our teams, who are committed to helping clients bring innovative therapies to patients.”
Judged on criteria including innovation, measurable outcomes, scalability, and regulatory compliance, the Excellence in Clinical Trial Management award recognizes CROs that set new standards in quality and execution. For Catalyst, the honor reaffirms its role as a key partner in clinical development and its mission to drive better outcomes for sponsors and patients alike.
The company stated it remains focused on delivering excellence across all trials and adapting to the evolving demands of the life sciences industry.
